Health and Fitness Health and Fitness
Fri, September 23, 2011
Thu, September 22, 2011
Wed, September 21, 2011
Tue, September 20, 2011
Mon, September 19, 2011
Sun, September 18, 2011
Sat, September 17, 2011
Fri, September 16, 2011
Thu, September 15, 2011
Wed, September 14, 2011
Tue, September 13, 2011
Mon, September 12, 2011
Sun, September 11, 2011
Sat, September 10, 2011
Fri, September 9, 2011
Thu, September 8, 2011
Wed, September 7, 2011
Tue, September 6, 2011
Mon, September 5, 2011
Sun, September 4, 2011
Sat, September 3, 2011
Fri, September 2, 2011
Thu, September 1, 2011
Wed, August 31, 2011
Tue, August 30, 2011
[ Tue, Aug 30th 2011 ] - Market Wire
00 a.m. ET
Mon, August 29, 2011
Fri, August 26, 2011
Thu, August 25, 2011
Wed, August 24, 2011

Geron to Webcast Presentations at Upcoming Investor Conferences


//health-fitness.news-articles.net/content/2011/ .. sentations-at-upcoming-investor-conferences.html
Published in Health and Fitness on Monday, September 12th 2011 at 4:46 GMT by Market Wire   Print publication without navigation


MENLO PARK, Calif.--([ BUSINESS WIRE ])--Geron Corporation (Nasdaq: GERN) today announced that management will present a company overview at two upcoming investor conferences.

  • Rodman & Renshaw Annual Global Investment Conference in New York City. David L. Greenwood, Gerona™s President and Chief Executive Officer, will present at 9:35 a.m. EDT on Tuesday, September 13, 2011.
  • UBS Global Life Sciences Conference in New York City. Hoyoung Huh, M.D., Ph.D., Gerona™s Executive Chairman, and Stephen M. Kelsey, M.D., Executive Vice President, Head of Research & Development and Chief Medical Officer will present at 10:30 a.m. on Wednesday, September 21, 2011.

The webcasts for the live audio and slide presentations will be available on the aInvestorsa pages of the companya™s website, [ www.geron.com ]. The presentations will be archived for replay and available on the Geron website one hour after conclusion of the live event.

About Geron

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a compound designed to penetrate the blood-brain barrier. The company is developing cell therapies from differentiated human embryonic stem cells for a range of indications, with the first product in a Phase 1 clinical trial for spinal cord injury. For more information, visit [ www.geron.com ].


Publication Contributing Sources